AbCellera Reports Positive Phase 2 Top-Line Results for ABCL635

What Happened

• AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. The company disclosed the news in a press release filed via Form 8-K on August 10, 2026.
• To discuss the results, AbCellera held an investor conference call and webcast on August 10, 2026 at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time). An investor presentation accompanying the announcement was made available on the company’s website.

Key Details

• Filing date: Form 8-K filed and dated August 10, 2026 (Regulation FD disclosure, Item 7.01).
• Documents furnished: Press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) were included with the 8-K.
• Drug and trial: ABCL635 is an investigational NK3R antagonist antibody; the announcement relates specifically to top-line Phase 2 results from the company’s Phase 1/2 trial.
• Signed by Carl L. G. Hansen, Ph.D., Chief Executive Officer, on behalf of AbCellera.

Why It Matters

• This filing provides an official, material update on AbCellera’s clinical development progress for ABCL635 and supplies supporting materials (press release and investor presentation) for investors to review.
• The investor webcast and posted presentation give market participants immediate access to management’s summary of the results and next steps announced by the company.